Omeros Corp (OMER) stock
OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.49−0.50 (-2.78%)
Close on Nov 13, 2026Market cap $1.27BP/E –Yield –
Omeros EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Omeros's EPS for the twelve months ending Sep 30, 2025 was -$2.02. For fiscal 2025 it was -$0.05. The highest annual figure on record is $3.12 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.05 | – |
| FY2024 | Dec 31, 2024 | -$2.70 | – |
| FY2023 | Dec 31, 2023 | -$1.88 | -347.4% |
| FY2022 | Dec 31, 2022 | $0.76 | -75.6% |
| FY2021 | Dec 31, 2021 | $3.12 | – |
| FY2020 | Dec 31, 2020 | -$2.41 | – |
| FY2019 | Dec 31, 2019 | -$1.71 | – |
| FY2018 | Dec 31, 2018 | -$2.61 | – |
| FY2017 | Dec 31, 2017 | -$1.17 | – |
| FY2016 | Dec 31, 2016 | -$1.65 | – |
| FY2015 | Dec 31, 2015 | -$2.00 | – |
| FY2014 | Dec 31, 2014 | -$2.22 | – |
| FY2013 | Dec 31, 2013 | -$1.39 | – |
| FY2012 | Dec 31, 2012 | -$1.59 | – |
| FY2011 | Dec 31, 2011 | -$1.29 | – |
| FY2010 | Dec 31, 2010 | -$1.37 | – |
| FY2009 | Dec 31, 2009 | -$2.92 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.15 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.62 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.47 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.43 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.58 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.54 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.56 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.97 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.63 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.15 | -107.3% |
| Q3 FY2023 | Sep 30, 2023 | -$0.60 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.59 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.54 | – |
| Q4 FY2022 | Dec 31, 2022 | $2.05 | -54.2% |
| Q3 FY2022 | Sep 30, 2022 | -$0.28 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.49 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.53 | – |
| Q4 FY2021 | Dec 31, 2021 | $4.48 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.57 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.60 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.66 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.61 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.53 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.58 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.33 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.29 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.50 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.48 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.81 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.70 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.62 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.34 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.16 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.33 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.34 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.45 | – |
| Q3 FY2016 | Sep 30, 2016 | -$0.34 | – |
| Q2 FY2016 | Jun 30, 2016 | -$0.32 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?